Aurinia Pharmaceuticals (NASDAQ: AUPH) lifts Q2 profit and backs 2026 outlook
Rhea-AI Filing Summary
Aurinia Pharmaceuticals Inc. reported strong financial results for the three and six months ended June 30, 2026. Total revenue reached $83.2 million for the quarter and $160.9 million year-to-date, up 19% and 21% from 2025, driven mainly by LUPKYNIS net product sales of $79.4 million and $153.0 million. Net income was $37.4 million for the quarter and $71.8 million for the first half, while diluted EPS rose to $0.28 and $0.53.
Cash flows from operating activities were $52.5 million in Q2 and $85.1 million for the first half, supporting cash, cash equivalents, restricted cash and investments of $443.1 million as of June 30, 2026. Aurinia repurchased 5.0 million common shares for $74.9 million. The company reiterated 2026 guidance for total revenue of $315 million to $325 million and LUPKYNIS net product sales of $305 million to $315 million. It also initiated PRESERVE, a Phase 4 study combining LUPKYNIS with biologic agents in lupus nephritis, and advanced aritinercept into clinical development in four potential autoimmune indications.
Positive
- Total revenue increased 19% year-over-year to $83.2 million in Q2 2026 and 21% to $160.9 million for the first half, reflecting growth in LUPKYNIS net product sales.
- Net income rose 74% in Q2 to $37.4 million and 60% in the first half, with diluted EPS up 75% to $0.28 and 66% to $0.53.
- Operating cash flow expanded 87% to $85.1 million for the first half of 2026, supporting a cash and investments balance of $443.1 million and enabling repurchase of 5.0 million shares.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenue Q2 2026: $83.2 million
Net income Q2 2026: $37.4 million
Diluted EPS Q2 2026: $0.28
+4 more
7 metrics
Total revenue Q2 2026
$83.2 million
Three months ended June 30, 2026; up 19% from $70.0 million in 2025.
Net income Q2 2026
$37.4 million
Three months ended June 30, 2026; up 74% from $21.5 million in 2025.
Diluted EPS Q2 2026
$0.28
Three months ended June 30, 2026; increased from $0.16 a year earlier.
Cash and investments
$443.1 million
Cash, cash equivalents, restricted cash and investments as of June 30, 2026.
Operating cash flow H1 2026
$85.1 million
Cash flows from operating activities for six months ended June 30, 2026; up from $45.5 million.
Share repurchase H1 2026
5.0 million shares for $74.9 million
Common shares repurchased under Share Repurchase Plan in the first half of 2026.
2026 revenue guidance
$315 million to $325 million
Full-year 2026 total revenue guidance, 11% to 15% above 2025.
Key Terms
lupus nephritis, Phase 4, complete renal response (CRR), B cell-activating factor (BAFF), +1 more
5 terms
lupus nephritis medical
"LUPKYNIS... oral therapy for the treatment of adult patients with active lupus nephritis."
Lupus nephritis is a condition in which a person’s immune system attacks the kidneys, causing inflammation and damage to the organs’ filtering function and leading to blood or protein in the urine and, in severe cases, kidney failure. For investors, it defines a specific, medically serious patient group and treatment need: success or failure of therapies, clinical trials, regulatory approvals, and pricing decisions for drugs aimed at this condition can meaningfully change a biotech or pharma company’s revenue prospects — like fixing a costly, central leak in a building that determines the value of the whole property.
Phase 4 medical
"Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study..."
Phase 4 is the stage after a drug or vaccine has been approved and is sold to the public, where regulators and companies keep watching how it performs in the real world to detect rare side effects, long‑term effects, or differences in effectiveness across different groups. Think of it as ongoing quality control for a product already on shelves; results can prompt label changes, safety warnings, sales impacts or recalls, all of which matter to investors evaluating risk and future revenue.
complete renal response (CRR) medical
"The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months."
B cell-activating factor (BAFF) medical
"Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both SLE and lupus nephritis."
Earnings Snapshot
Total revenue (Q2 2026): $83.2 million · Guidance included
three and six months ended June 30, 2026
Total revenue (Q2 2026)
$83.2 million
up 19% from $70.0 million in Q2 2025
Net income (Q2 2026)
$37.4 million
up 74% from $21.5 million in Q2 2025
Diluted EPS (Q2 2026)
$0.28
up 75% from $0.16 in Q2 2025
Operating cash flows (H1 2026)
$85.1 million
up 87% from $45.5 million in H1 2025
2026 total revenue guidance
$315 million to $325 million
up 11% to 15% compared to 2025
Guidance
Aurinia reiterated 2026 guidance for total revenue of $315 million to $325 million and LUPKYNIS net product sales of $305 million to $315 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Aurinia Pharmaceuticals (AUPH) perform financially in Q2 2026?
Aurinia reported Q2 2026 total revenue of $83.2 million, up 19% from 2025, and net income of $37.4 million, up 74%. Diluted EPS rose to $0.28 from $0.16, reflecting strong growth in LUPKYNIS net product sales and improved profitability.
What were Aurinia Pharmaceuticals' (AUPH) LUPKYNIS net product sales in Q2 and H1 2026?
LUPKYNIS net product sales were $79.4 million in Q2 2026 and $153.0 million for the first half, up 19% and 21% from the same periods in 2025. These sales were the primary driver of Aurinia’s overall revenue growth.
What 2026 revenue guidance did Aurinia Pharmaceuticals (AUPH) reiterate?
Aurinia reaffirmed 2026 total revenue guidance of $315 million to $325 million, 11% to 15% above 2025, and LUPKYNIS net product sales guidance of $305 million to $315 million, 12% to 16% higher than 2025, indicating continued expected growth.
What is Aurinia Pharmaceuticals' (AUPH) cash position and capital allocation as of June 30, 2026?
As of June 30, 2026, Aurinia held $443.1 million in cash, cash equivalents, restricted cash and investments. Operating cash flow was $85.1 million in the first half, and the company repurchased 5.0 million common shares for $74.9 million under its Share Repurchase Plan.
What clinical development updates did Aurinia Pharmaceuticals (AUPH) provide in this report?
Aurinia initiated PRESERVE, a Phase 4 study testing LUPKYNIS plus belimumab, obinutuzumab or anifrolumab in lupus nephritis, targeting about 150 patients at 50 U.S. sites. The primary endpoint is complete renal response at 6 months. Aurinia also advanced aritinercept into four potential autoimmune indications.
How did Aurinia Pharmaceuticals' (AUPH) operating cash flow change in the first half of 2026?
Cash flows from operating activities were $85.1 million for the six months ended June 30, 2026, up 87% from $45.5 million in 2025. This improvement reflects higher profitability and working capital movements, strengthening the company’s liquidity profile.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||||||||
(250 ) 744-2487
(Address and telephone number of registrant's principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition | ||||
On August 6, 2026, Aurinia Pharmaceuticals Inc. (“Aurinia”) issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1.
The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits | ||||
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Earnings release dated August 6, 2026 | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2026
| AURINIA PHARMACEUTICALS INC. | ||||||||
| By: | /s/ Michael Hearne | |||||||
| Name: | Michael Hearne | |||||||
| Title: | Chief Financial Officer | |||||||
| Exhibit 99.1 | ||||||||
 | ||||||||
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Maryland and EDMONTON, Alberta – August 6, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress.
Financial Results
•Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025.
–Net Product Sales: For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $79.4 million and $153.0 million, up 19% and 21%, respectively, from $66.6 million and $126.5 million, respectively, in the same periods of 2025.
–License, Collaboration and Royalty Revenue: For the three and six months ended June 30, 2026, license, collaboration and royalty revenue was $3.8 million and $8.0 million, up 12% and 36%, respectively, from $3.4 million and $5.9 million, respectively, in the same periods of 2025.
•Net Income: For the three and six months ended June 30, 2026, net income was $37.4 million and $71.8 million, up 74% and 60%, respectively, from $21.5 million and $44.9 million, respectively, in the same periods of 2025.
•Diluted Earnings per Share: For the three and six months ended June 30, 2026, diluted earnings per share was $0.28 and $0.53, up 75% and 66%, respectively, from $0.16 and $0.32 in the same periods of 2025.
•Cash Flows from Operating Activities: For the three and six months ended June 30, 2026, cash flows from operating activities were $52.5 million and $85.1 million, up 19% and 87%, respectively, from $44.2 million and $45.5 million in the same periods of 2025.
Cash Position
As of June 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025. For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company’s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million.
2026 Total Revenue and Net Product Sales Guidance
Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.
Recent Development Progress
LUPKYNIS
Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the
1
multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.
Aritinercept
Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.
Investor Inquiries
ir@auriniapharma.com
2
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| June 30, 2026 | December 31, 2025 | |||||||||||||
| (Unaudited) | ||||||||||||||
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash, cash equivalents and restricted cash | $ | 179,832 | $ | 80,213 | ||||||||||
| Short-term investments | 263,291 | 317,784 | ||||||||||||
| Accounts receivable, net | 41,138 | 41,454 | ||||||||||||
| Inventory | 45,151 | 45,690 | ||||||||||||
Prepaid expenses and deposits | 10,531 | 5,746 | ||||||||||||
| Other current assets | 1,381 | 1,080 | ||||||||||||
| Total current assets | 541,324 | 491,967 | ||||||||||||
Deferred tax assets, net | 178,935 | 176,194 | ||||||||||||
| Finance right-of-use lease assets | 65,152 | 73,865 | ||||||||||||
| Intangible assets, net | 3,378 | 3,761 | ||||||||||||
| Operating right-of-use lease assets | 1,518 | 3,596 | ||||||||||||
| Property and equipment, net | 1,862 | 2,111 | ||||||||||||
| Other noncurrent assets | 93 | 93 | ||||||||||||
| Total assets | $ | 792,262 | $ | 751,587 | ||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 1,735 | $ | 3,313 | ||||||||||
| Accrued expenses | 64,112 | 66,621 | ||||||||||||
| Finance lease liabilities, current portion | 16,479 | 16,523 | ||||||||||||
| Deferred revenue | 10,593 | 3,720 | ||||||||||||
| Operating lease liabilities, current portion | 1,705 | 1,067 | ||||||||||||
| Other current liabilities | 5,269 | 2,480 | ||||||||||||
| Total current liabilities | 99,893 | 93,724 | ||||||||||||
| Finance lease liabilities, less current portion | 43,943 | 52,322 | ||||||||||||
| Deferred tax benefits | 23,128 | — | ||||||||||||
| Deferred revenue, less current portion | 7,480 | 12,648 | ||||||||||||
| Operating lease liabilities, less current portion | 2,009 | 4,900 | ||||||||||||
| Other noncurrent liabilities | 945 | 6,662 | ||||||||||||
| Total liabilities | 177,398 | 170,256 | ||||||||||||
| Shareholders' equity | ||||||||||||||
| Common shares — no par value, unlimited shares authorized, 132,907 and 132,323 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,117,248 | 1,120,035 | ||||||||||||
| Additional paid-in capital | 76,192 | 111,263 | ||||||||||||
| Accumulated other comprehensive loss | (977) | (599) | ||||||||||||
| Accumulated deficit | (577,599) | (649,368) | ||||||||||||
| Total shareholders' equity | 614,864 | 581,331 | ||||||||||||
| Total liabilities and shareholders' equity | $ | 792,262 | $ | 751,587 | ||||||||||
3
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||
Net product sales | $ | 79,412 | $ | 66,574 | $ | 152,975 | $ | 126,545 | ||||||||||||||||||
License, collaboration and royalty revenue | 3,808 | 3,434 | 7,950 | 5,928 | ||||||||||||||||||||||
Total revenue | 83,220 | 70,008 | 160,925 | 132,473 | ||||||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||||
| Cost of revenue | 6,555 | 7,115 | 13,060 | 15,689 | ||||||||||||||||||||||
| Selling, general and administrative | 23,508 | 26,018 | 45,537 | 46,357 | ||||||||||||||||||||||
| Research and development | 13,050 | 7,432 | 20,520 | 13,175 | ||||||||||||||||||||||
| Restructuring | — | 114 | — | 1,647 | ||||||||||||||||||||||
| Other (income) expense, net | (6,234) | 9,246 | (5,955) | 13,675 | ||||||||||||||||||||||
| Total operating expenses | 36,879 | 49,925 | 73,162 | 90,543 | ||||||||||||||||||||||
| Income from operations | 46,341 | 20,083 | 87,763 | 41,930 | ||||||||||||||||||||||
| Interest income | 3,393 | 3,190 | 6,908 | 6,759 | ||||||||||||||||||||||
| Interest expense | (948) | (1,117) | (1,960) | (2,184) | ||||||||||||||||||||||
| Net income before income taxes | 48,786 | 22,156 | 92,711 | 46,505 | ||||||||||||||||||||||
| Income tax expense | 11,372 | 643 | 20,942 | 1,648 | ||||||||||||||||||||||
| Net income | $ | 37,414 | $ | 21,513 | $ | 71,769 | $ | 44,857 | ||||||||||||||||||
| Earnings per share | ||||||||||||||||||||||||||
| Basic | $ | 0.29 | $ | 0.16 | $ | 0.55 | $ | 0.33 | ||||||||||||||||||
| Diluted | $ | 0.28 | $ | 0.16 | $ | 0.53 | $ | 0.32 | ||||||||||||||||||
| Shares used in computing earnings per share | ||||||||||||||||||||||||||
| Basic | 130,081 | 134,873 | 131,221 | 136,878 | ||||||||||||||||||||||
| Diluted | 133,530 | 137,526 | 135,518 | 140,193 | ||||||||||||||||||||||
4
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
| Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||
Net income | $ | 71,769 | $ | 44,857 | ||||||||||
| Adjustments to reconcile net income to cash flows from operating activities: | ||||||||||||||
| Deferred income tax | 20,387 | — | ||||||||||||
| Share-based compensation | 1,973 | 2,031 | ||||||||||||
| Amortization and depreciation | 9,650 | 9,720 | ||||||||||||
| Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | (977) | 9,265 | ||||||||||||
| Net amortization of premiums and discounts on investments | (4,200) | (5,219) | ||||||||||||
| Other, net | (2,082) | 4,132 | ||||||||||||
| Net changes in operating assets and liabilities: | ||||||||||||||
| Accounts receivable, net | 316 | (3,547) | ||||||||||||
Inventory | 539 | (7,275) | ||||||||||||
| Prepaid expenses and other current assets | (5,031) | 5,106 | ||||||||||||
| Other noncurrent operating assets | — | 730 | ||||||||||||
| Accounts payable | (3,451) | (1,875) | ||||||||||||
| Accrued expenses and other liabilities | (5,031) | (17,136) | ||||||||||||
| Deferred revenue | 1,705 | 5,147 | ||||||||||||
| Operating lease liabilities | (441) | (395) | ||||||||||||
| Cash flows from operating activities | 85,126 | 45,541 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Proceeds from the sale and maturities of investments | 209,000 | 255,285 | ||||||||||||
| Purchases of investments | (150,805) | (237,411) | ||||||||||||
| Net cash and cash equivalents acquired in acquisition of Kezar | 5,212 | — | ||||||||||||
| Purchases of property, equipment and intangible assets | (39) | (115) | ||||||||||||
| Cash flows from investing activities | 63,368 | 17,759 | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Purchase of common shares under Share Repurchase Plan | (74,880) | (89,485) | ||||||||||||
Payments of principal portion of Monoplant finance lease liability | (7,058) | (6,201) | ||||||||||||
Proceeds from issuance of common shares for equity awards | 59,154 | 10,590 | ||||||||||||
Proceeds from issuance of common shares under ESPP | 363 | 401 | ||||||||||||
| Tax withholding payments related to net settlements of equity awards | (26,454) | (9,036) | ||||||||||||
| Cash flows from financing activities | (48,875) | (93,731) | ||||||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 99,619 | (30,431) | ||||||||||||
| Cash, cash equivalents and restricted cash, beginning of the period | 80,213 | 83,433 | ||||||||||||
| Cash, cash equivalents and restricted cash, end of the period | $ | 179,832 | $ | 53,002 | ||||||||||
5